2009
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young A, Oren D, Lowy A, McQuade R, Marcus R, Carson W, Spiller N, Torbeyns A, Sanchez R. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. The British Journal Of Psychiatry 2009, 194: 40-48. PMID: 19118324, DOI: 10.1192/bjp.bp.108.049965.Peer-Reviewed Original ResearchConceptsWeek 12Young Mania Rating Scale (YMRS) total scoreDouble-blind aripiprazoleHaloperidol-treated patientsTolerability of aripiprazoleExtrapyramidal adverse eventsScale total scoreMasked treatmentAdverse eventsClinical improvementAcute maniaAripiprazole monotherapyBipolar maniaMixed episodesEffective therapyEffect therapyAripiprazoleAdditional weeksHaloperidolWeek 3PlaceboPatientsTotal scoreTherapyMania
2007
Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations
DANIEL D, CURRIER G, ZIMBROFF D, ALLEN M, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations. Journal Of Psychiatric Practice 2007, 13: 170-177. PMID: 17522560, DOI: 10.1097/01.pra.0000271658.86845.81.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAgedAntipsychotic AgentsAripiprazoleDouble-Blind MethodDyskinesia, Drug-InducedFemaleHaloperidolHumansInjections, IntramuscularMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaConceptsOral aripiprazoleOral formulationHaloperidol IMOral phaseIntramuscular formulationEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPrimary efficacy measureStudy days 1Negative Syndrome ScalePlacebo IMAcute treatmentAdverse eventsGood tolerabilityClinical statusMean changePEC scoresPatientsDay 1HaloperidolAripiprazoleSyndrome ScaleInitial benefitComponent scoresIntramuscular Aripiprazole in the Control of Agitation
CURRIER G, CITROME L, ZIMBROFF D, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Intramuscular Aripiprazole in the Control of Agitation. Journal Of Psychiatric Practice 2007, 13: 159-169. PMID: 17522559, DOI: 10.1097/01.pra.0000271657.09717.e2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAripiprazoleArousalBipolar DisorderDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHaloperidolHumansHypnotics and SedativesInjections, IntramuscularLorazepamMaleMiddle AgedMulticenter Studies as TopicPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationQuinolonesRandomized Controlled Trials as TopicSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsBipolar I disorderPEC scoresAripiprazole injectionI disordersBaseline agitationSecond injectionNegative Syndrome Scale Excited ComponentBaseline levelsSecondary analysisControl of agitationImportant clinical issueIntramuscular aripiprazoleAnalysis 3Clinical trialsAgitation symptomsMean changeNonspecific sedationPatientsBaseline scoresClinical issuesPlaceboAnalysis 2Analysis 1Study periodSchizophrenia
2006
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study*
Andrezina R, Marcus R, Oren D, Manos G, Stock E, Carson W, McQuade R. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study*. Current Medical Research And Opinion 2006, 22: 2209-2219. PMID: 17076982, DOI: 10.1185/030079906x148445.Peer-Reviewed Original ResearchConceptsDouble-blind studyIM haloperidolIM placeboIntramuscular aripiprazoleIM aripiprazoleOral aripiprazoleOral therapyEfficacy measuresIM treatmentPEC scoresExtrapyramidal symptom-related adverse eventsSecondary efficacy measuresPrimary efficacy measureAripiprazole therapyAcute agitationAdverse eventsOral treatmentActive treatmentSafety profileIM injectionMean changeMean improvementPlaceboHaloperidolAripiprazoleIntramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
Andrezina R, Josiassen R, Marcus R, Oren D, Manos G, Stock E, Carson W, Iwamoto T. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006, 188: 281-292. PMID: 16953381, DOI: 10.1007/s00213-006-0541-x.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAnti-Dyskinesia AgentsAntipsychotic AgentsAripiprazoleBasal Ganglia DiseasesBenzodiazepinesBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationFemaleHaloperidolHumansInjections, IntramuscularMalePiperazinesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaTime FactorsTreatment OutcomeWithholding TreatmentConceptsIM aripiprazoleIM haloperidolAcute agitationIntramuscular aripiprazoleEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPlacebo-controlled studySecondary efficacy measuresPercentage of patientsPlacebo-controlled comparisonPrimary efficacy measureIM placeboIntramuscular haloperidolAdverse eventsMethodsFour hundredThird injectionMean changePlaceboEffective treatmentHaloperidolPatientsAripiprazoleConclusionThese resultsMean number